Status:
COMPLETED
Comparison Study of Transarterial Chemoembolization and Percutaneous Ethanol Injection for Multiple, Small HCCs
Lead Sponsor:
Seoul National University Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
20-70 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to choose the preferred treatment modality for multiple, small hepatocellular carcinomas.
Detailed Description
To compare the below things between PEIT group and TACE group 1. Survival 1. 5 year overall survival rate 2. Disease free survival rate 2. Recurrence a. recurrence rate
Eligibility Criteria
Inclusion
- The evidences of HBV(+) \&/or HCV(+) infection or liver cirrhosis
- Two to three tumor nodules with Child-Pugh classification A or single to three tumor nodules with Child-Pugh classification B
- The maximal, longest diameter of tumor mass measured by CT finding should be less than 2 cm.
- 1\) Only for newly detected HCCs which were not treated before or 2) If treated before, it should be noted that there is no evidence of recurrence within the latest 6 months and, and also it should be remotely recurred more than 2cm apart from primary lesion.
- It should be compatible with the typical findings of HCCs radiologically(MD CT or dynamic MRI)
Exclusion
- In case of hepatic vein or portal vein invasion radiologically(CT or MRI)
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00357474
Start Date
October 1 2005
End Date
February 1 2012
Last Update
December 4 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul NUH
Seoul, Chongno-gu, South Korea, 110-744